Saliva soluble HLA as a potential marker of response to interferon-β1a in multiple sclerosis: A preliminary study

被引：0
|
作者：
Alireza Minagar
Irena Adamashvili
Roger E Kelley
Eduardo Gonzalez-Toledo
Jerry McLarty
Stacy J Smith
机构：
[1] LSU Health Sciences Center,Department of Neurology
[2] LSU Health Sciences Center,Department of Radiology
[3] LSU Health Sciences Center,Department of Internal Medicine
来源：
Journal of Neuroinflammation | / 4卷
关键词：
Multiple Sclerosis; Multiple Sclerosis Patient; Optic Neuritis; Natalizumab; RRMS Patient;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Overview of London trial of intramuscular interferon-β1a in primary-progressive multiple sclerosis
    Miller, DH
    Leary, SM
    Thompson, AJ
    MULTIPLE SCLEROSIS JOURNAL, 2004, 10 : S56 - S57
  • [42] Rapid-Onset Psychotic Symptoms After Interferon-β-1a Treatment of Multiple Sclerosis
    Huang, Jing-Syuan
    Chang, Chuan-Chia
    Tai, Yueh-Ming
    Huang, Chien-Peng
    Chen, Shyi-Jou
    Tzeng, Nian-Sheng
    AMERICAN JOURNAL OF THERAPEUTICS, 2020, 27 (06) : E627 - E629
  • [43] Lobular panniculitis and lipoatrophy of the thighs with interferon-β1a for intramuscular injection in a patient with multiple sclerosis
    Weise, Gesa
    Hupp, Markus
    Kerstan, Andreas
    Buttmann, Mathias
    JOURNAL OF CLINICAL NEUROSCIENCE, 2012, 19 (09) : 1312 - 1313
  • [44] Intramuscular interferon-β-1a -: In patients at high risk of developing clinically definite multiple sclerosis
    Asif, M
    Siddiqui, A
    Wellington, K
    CNS DRUGS, 2005, 19 (01) : 55 - 61
  • [45] Hepatic reactions during treatment of multiple sclerosis with interferon-β-1a -: Incidence and clinical significance
    Francis, GS
    Grumser, Y
    Alteri, E
    Micaleff, A
    O'Brien, F
    Alsop, J
    Moraga, MS
    Kaplowitz, N
    DRUG SAFETY, 2003, 26 (11) : 815 - 827
  • [46] Should patients with relapsing multiple sclerosis be given a higher dose and frequency of interferon-β1a?
    Robert J Fox
    Richard A Rudick
    Nature Clinical Practice Neurology, 2005, 1 : 16 - 17
  • [47] Should patients with relapsing multiple sclerosis be given a higher dose and frequency of interferon-β1a?
    Fox, RJ
    Rudick, RA
    NATURE CLINICAL PRACTICE NEUROLOGY, 2005, 1 (01): : 16 - 17
  • [48] Spotlight on subcutaneous recombinant interferon-β-1a (Rebif®) in relapsing-remitting multiple sclerosis
    Murdoch, D
    Lyseng-Williamson, KA
    BIODRUGS, 2005, 19 (05) : 323 - 325
  • [49] Intramuscular interferon-β-1a: In patients at high risk of developing clinically definite multiple sclerosis
    Siddiqui M.A.A.
    Wellington K.
    CNS Drugs, 2005, 19 (1) : 55 - 61
  • [50] Reduction of IL9 may be an early response marker for interferon β 1a treatment in multiple sclerosis patients
    Kurtuncu, M.
    Tuzun, E.
    Petek-Balci, B.
    Birday, E.
    Coban, A.
    Turkoglu, R.
    Icoz, S.
    Pehlivan, M.
    Ulusoy, C.
    Akman-Demir, G.
    Eraksoy, M.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 450 - 450
12345